Telix Pharmaceuticals Limited American Depositary Shares (TLX)

About TLX

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clini…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

1,120

Fundamentals

1-day range

$11.21$11.47

Market cap

$3.60B

P/E (trailing)

—

P/E (forward)

77.45

EPS (trailing)

—

Dividend yield

—

Beta

—

Avg. volume

165.0K

Telix Pharmaceuticals Limited American Depositary Shares Competitors

Chosen by industry and closest market cap.

• TLX

  Telix Pharmaceuticals Limited American Depositary Shares

  $11.28

  ▼ 0.84%
  Market cap $3.60BP/E —
  $6.28$12.5
• ALMS

  Alumis Inc. Common Stock

  $22.38

  ▼ 3.58%
  Market cap $3.54BP/E —
  $3.76$31.35
• ELVN

  Enliven Therapeutics Inc. Common Stock

  $57.82

  ▼ 4.43%
  Market cap $3.67BP/E —
  $14.79$62.32
• GPCR

  Structure Therapeutics Inc. American Depositary Shares

  $47.38

  ▼ 3.74%
  Market cap $3.74BP/E —
  $18.26$94.9
• VKTX

  Viking Therapeutics Inc. Common Stock

  $32.15

  ▼ 5.05%
  Market cap $3.88BP/E —
  $22.96$43.15
• ARQT

  Arcutis Biotherapeutics Inc. Common Stock

  $23.78

  ▼ 4.38%
  Market cap $3.31BP/E 113.86
  $15.1$31.77
• NAMS

  NewAmsterdam Pharma Company N.V. Ordinary Shares

  $25.9

  ▼ 3.32%
  Market cap $3.23BP/E —
  $23.05$42.21

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• 12 Health Care Stocks Moving In Friday's Pre-Market Session
  Benzinga · 8/21/2026
• Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target
  benzinga · 8/20/2026
• Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target
  Benzinga · 8/20/2026
• Reported Earlier, Telix Pharmaceuticals Guides FY 2026 Revenue Of $950M-$970M, Total Income Above $1B, Reaffirms R&D Guidance Of $230M-$270M
  Benzinga · 8/20/2026
• Telix Pharmaceuticals Limited (TLX) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/20/2026
• Telix Pharmaceuticals Limited 2026 Q2 - Results - Earnings Call Presentation
  SeekingAlpha · 8/20/2026
• Telix to Host R&D Day in New York City on September 22, 2026
  Yahoo · 8/5/2026
• Telix Pharmaceuticals: The Radiopharma Operating System Is The Real Moat
  SeekingAlpha · 7/31/2026

• Behrenbruch Christian · April 29, 2026 · Buy

  33.4K @ $14.87
• Behrenbruch Christian · April 28, 2026 · Buy

  34.5K @ $14.48
• Smith Darren Charlton · March 29, 2026 · Option Exercise

  1.1K

Institutional Ownership

March 31, 2026

Total shares held

2.51M

Total value held

$23.95M

Institutional holders

37